SecBot SecBot
6-K ·Filed Apr 23, 2026

PPBT

PURPLE BIOTECH LTD.
NEUTRAL
Impact 3/10
Horizonmonths Processed6mo ago SEC0001213900-26-046868
Notable filing: 6-K
Actionable Insight • Neutral

Monitor upcoming regulatory filings or clinical trial announcements for progress updates on the CAPTN-3 platform. The SAB formation signals strategic focus but does not alter near-term valuation without additional data.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.55
T+0 close · Apr 23, 2026 · via day close
Latest settled
−68.13%
T+60 · $1.45
Vs SPY
−73.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 23 $4.55entry
  2. T+1 · 7mo ago −0.22%α −1.00% · $4.54
  3. T+5 · 7mo ago −7.03%α −8.51% · $4.23
  4. T+20 · 6mo ago −34.51%α −39.14% · $2.98
  5. T+60 · 4mo ago −68.13%α −73.15% · $1.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Purple Biotech announced the formation of a Scientific Advisory Board (SAB) composed of leading experts in immunotherapy and oncology to guide the development of its CAPTN-3 tri-specific antibody platform. The SAB includes specialists in T-cell and NK cell biology with direct experience in developing approved T-cell engager therapies.

Key Facts

  • Purple Biotech established a Scientific Advisory Board (SAB) to support development of its CAPTN-3 tri-specific antibody platform.
  • SAB members include Dr. Amir Horowitz (NK cell biology), Dr. Afshin Dowlati (early-phase clinical development in solid tumors), Dr. Alexander Shoushtari (melanoma and T-cell engager development), and Dr. Max S. Topp (early clinical development of blinatumomab).
  • The CAPTN-3 platform is in preclinical development and focuses on masked tri-specific antibodies targeting 5T4 (IM1240) and TROP2 (IM1305).
  • No financial terms, clinical data, or material agreements were disclosed in the filing.

Financial Impact

No immediate financial impact; advisory board formation is a strategic development without direct monetary implications.

Risk Factors

  • CAPTN-3 remains in preclinical development with no guarantee of successful clinical translation.
  • Company has limited financial resources (market cap $5M) and may require future capital raises, potentially dilutive to shareholders.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-046868
Document: ea0286950-6k_purple.htm0001213900-26-046868
Document: 0001213900-26-046868-index-headers.html0001213900-26-046868
Document: 0001213900-26-046868-index.html0001213900-26-046868
Document: 0001213900-26-046868.txt0001213900-26-046868

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026